首页/数据集/Human dermal fibroblasts (HDF), BRAF-V600E positive (MaMel21 and MaMel63a), and BRAF-WT malignant melanoma cell lines (SBcl2 and WM3438) after vemurafenib or DMSO treatment

Human dermal fibroblasts (HDF), BRAF-V600E positive (MaMel21 and MaMel63a), and BRAF-WT malignant melanoma cell lines (SBcl2 and WM3438) after vemurafenib or DMSO treatment

NIAID Data Ecosystem2026-03-14 收录

黑色素瘤药物反应

BRAF抑制剂耐药性

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE188470 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2022-12-05

BRAF抑制剂耐药性

肉芽肿反应研究

Supplementary files for 'BRAF inhibition and the spectrum of granulomatous reactions: A review', in publication by the Journal of the American Academy of Dermatology.

Mendeley Data50

RNA-seq for human dermal fibroblasts (HDF), BRAF-V600E positive (MaMel21 and MaMel63a), and BRAF-WT malignant melanoma cell lines (SBcl2 and WM3438) after vemurafenib or DMSO treatment. RNA-seq for human dermal fibroblasts (HDF), BRAF-V600E positive (MaMel21 and MaMel63a), and BRAF-WT malignant melanoma cell lines (SBcl2 and WM3438) after vemurafenib or DMSO treatment

黑色素瘤药物反应

肿瘤微环境重构

Background: Vemurafenib (PLX4032) is one of the most frequently used treatments for late-stage melanoma patients with the BRAFV600E mutation; however, acquired resistance to the drug remains as a majo

NIAID Data Ecosystem40

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping

BRAF抑制剂耐药性

表观遗传图谱

In this report, we generated eight matched pairs of vemurafenib sensitive/resistant melanoma lines and subjected these to concurrent RNA-seq and H3K27Ac ChIP-seq analysis. Globally, we identified two

NIAID Data Ecosystem30

Human WM35 melanoma cell line treated with ciclopirox and crizotinib. Homo sapiens

黑色素瘤药物反应

预后基因特征

To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75,

NIAID Data Ecosystem50

Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges

BRAF抑制剂耐药性

黑色素瘤靶向治疗

Focal amplifications (FAs) resulting in copy number gain of targeted genomic regions can mediate targeted therapy resistance. Understanding the structure, plasticity and vulnerability of FAs is critic

NIAID Data Ecosystem30

Human dermal fibroblasts (HDF), BRAF-V600E positive (MaMel21 and MaMel63a), and BRAF-WT malignant melanoma cell lines (SBcl2 and WM3438) after vemurafenib or DMSO treatment

资源简介：

相关数据集